RegeneRx Biopharmaceuticals, Inc. (RGRX)

USD 0.07

(0.0%)

Market Cap (In USD)

109.72 Thousand

Revenue (In USD)

76.76 Thousand

Net Income (In USD)

-1.72 Million

Avg. Volume

207.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.001-0.0733
PE
-
EPS
-
Beta Value
2.77
ISIN
US75886X1081
CUSIP
75886X108
CIK
707511
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. J. J. Finkelstein
Employee Count
-
Website
https://www.regenerx.com
Ipo Date
2003-10-07
Details
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.